Cytoreason融资
WebSep 21, 2024 · Pfizer and CytoReason have expanded their multi-year collaboration to leverage the latter’s artificial intelligence (AI) technology to discover and develop the former’s drug programmes.. According to the deal, Pfizer will invest $20m in equity, hold options for licencing the platform and disease models of CytoReason, and provide … WebCytoReason is located in Tel Aviv, Tel Aviv, Israel. Who invested in CytoReason? CytoReason has 3 investors including Pfizer and …
Cytoreason融资
Did you know?
WebApr 12, 2024 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases ... WebSep 20, 2024 · Pharmaceutical giant Pfizer is making a $20 million investment in Israeli firm CytoReason, a developer of computational disease models for drug discovery and development, as part of a wider deal ...
WebCytoReason has raised a total of $20M in funding over 3 rounds. Their latest funding was raised on Sep 20, 2024 from a Corporate Round round. Which funding types raised the … WebSep 30, 2024 · CytoReason's computational model of the human body simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate. With ...
WebCytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases - tissue by tissue, cell by cell. With CytoReason's massive database and AI-led platform, pharma and biotech companies can identify new … WebJul 30, 2024 · CytoReason was founded in 2016 by researchers and scientists from the Technion-Israel Institute of Technology. It was founded with the goal of leveraging new technology to address the increasing ...
Web智药局. 近日,一家由中科院孵化而出的AI制药公司拿下近亿元A轮融资,进入了大众的视野。. 与大部分AI制药公司不同的是,哲源科技选择从大量的医学文献和数据中,试图用 “知识+数据+超算+人工智能” 的方式分析数据,找到疾病的发病机制。. 全球AI+疾病 ...
WebNov 16, 2024 · 根据协议条款,辉瑞将进行2000万美元的股权投资,拥有许可CytoReason平台和疾病模型的选择权,并资助补充项目,这笔交易在未来五年内的价值可能高达1.1亿 … cisco room 70 single screen floor stand kitWebJun 17, 2024 · TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug … diamond shaped floating candlesWebJan 23, 2024 · TEL AVIV, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CytoReason, a leader and pioneer in computational disease modeling, today announced an expansion … diamond shaped gift boxWebWhat’s needed is a technology capable of digesting, organizing and making sense of all data types and sources. We founded CytoReason in 2016 to address this problem. Our computational disease models are designed … diamond shaped giftsWebCytoReason General Information. Description. Provider of cell-based models and data analysis services intended to develop a computational model of the human body that simulates human disease on a cellular level. The company's platform uses a proprietary data and machine learning (ML) model to reconstruct cellular information from bulk tissue ... diamond shaped fossilWebJan 7, 2024 · About CytoReason. Based on more than 10 years of research, CytoReason’s technology uses a proprietary data and machine learning model to reconstruct cellular information from bulk tissue, to ... diamond shaped fruit snacksWebFunding. CytoReason has raised a total of $20M in funding over 3 rounds. Their latest funding was raised on Sep 20, 2024 from a Corporate Round round. CytoReason is funded by 3 investors. Pfizer and Asymmetry Ventures are the most recent investors. diamond shaped gems